Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)

Name: Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)
Published: 2018
License: Public Domain

Memorial Sloan Kettering Cancer Center · 2018

ClinicalTrials.gov · Datasets · License: Public Domain · 2018

Open Source ↗

acute myeloid leukemia (aml), minimal residual disease, azacitidine, avelumab, 18-012, interventional, phase1, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)

Related documents